Whole-body positron emission tomography (PET) with fluorodeoxyglucose (FDG) is fast becoming the standard of care in management of a variety of malignant and nonmalignant conditions. Two excellent reviews by Rohren et al. (1) and Kostakoglu et al. (2) describe the clinical applications of PET in oncology in adult patients. As more experience is gained in the pediatric population, indications for pediatric FDG-PET imaging are emerging (3-5).
ASJC Scopus subject areas